AKT1 and ovarian carcinoma: Compared with the ES‐2 ovarian cancer cell line that is cisplatin‐sensitive, overexpression of Rab25 promotes PI3K/AKT signaling in SKOV‐3 ovarian cancer cells that are cisplatin‐resistant (Fan et al. 2015).